Income statement
USD
Annual
| Metric | 2016 | 2015 | 2014 |
|---|---|---|---|
| Revenue | 0 | 375K | 1M |
| Gross Profit | 0 | 375K | 1M |
| Operating Income | -18M | -6M | -6M |
| EBITDA | -18M | -5M | -5M |
| Net Income | -20M | -7M | -7M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PhaseRx, Inc. (PZRXQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -185.1%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -185.1%, free cash flow -63.8% with operating margin 0.0% and ROIC -122.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PZRXQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PZRXQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PZRXQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PZRXQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
+220.0% YoY
FY Net Income
-$6.8M
+7.2% YoY
Free Cash Flow
-$4.9M
+19.4% YoY
Revenue Growth
-100.0%
EPS Growth
-185.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2016 | 2015 | 2014 |
|---|---|---|---|
| Revenue | 0 | 375K | 1M |
| Gross Profit | 0 | 375K | 1M |
| Operating Income | -18M | -6M | -6M |
| EBITDA | -18M | -5M | -5M |
| Net Income | -20M | -7M | -7M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2016 | 2015 | 2014 |
|---|---|---|---|
| Cash & Equivalents | 10M | 3M | 2M |
| Total Assets | 16M | 4M | 3M |
| Total Liabilities | 7M | 53M | 44M |
| Shareholder Equity | 9M | -49M | -42M |
| Total Debt | 6M | 20M | 13M |
| Net Debt | -4M | 17M | 11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+18.7% YoY
Capital Expenditures
53K
+53.5% YoY
Free Cash Flow
5M
+19.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
101.7%
Debt / Equity
0.61x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.